Press Releases


Foundation Medicine Receives FDA Approval of FoundationFocus™ CDxBRCA as a Companion Diagnostic for Rubraca™ (rucaparib) for the Treatment of Women with Ovarian Cancer

--First and only companion diagnostic to detect tumor BRCA1/2 alterations, potentially increasing the number of women who are eligible for Rubraca (rucaparib) therapy-- --FDA approval of FoundationFocus CDxBRCA marks important progress towards Foundation Medicine's development of a compre...

Read More

... Next